Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery

Pain Clinical Trial

Official title:

Study of Posterior Lumbar Plexus Block for Pain Relief After Hip Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00150865
• Other study ID #: CP 02-01
• Status: Completed
• Phase: N/A
• First received: September 7, 2005
• Last updated: October 30, 2017
• Start date: September 2001
• Est. completion date: March 2002

Study information

• Verified date: September 2005
• Source: University Hospital, Angers
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Compare lumbar plexus block with ropivacaine 0.475%, 0.4 ml/kg to saline. Each group randomized, includes 30 patients. block performed preoperatively Surgery under general anesthesia. Postoperative evaluation of pain (VAS) as first endpoint, and also morphine consumption via PCA device. Follow-up : 24h.

Expectation : sizeable reduction of pain with block, of duration.

Description:

Compare lumbar plexus block (randomized)

• ropivacaine 0.475%, 0.4 ml/kg

• saline 0.4 ml/kg . Each group includes 30 patients.

Block performed preoperatively.

Surgery under general anesthesia (sufentanil, propofol, atracurium ; maintenance :

sevoflurane and nitrous oxide in O2. Sufentanil added peroperatively as clinically needed.

Postoperative evaluation of pain (VAS, by an independant blind observer) as first endpoint, and also morphine consumption via PCA device.

Adverse effects (nausea, vomiting, etc) recorded

Follow-up : 24h. Expectation : sizeable reduction of pain with block, of duration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 2002
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• adults

• ASA 1-3

Exclusion Criteria:

• cognitive impairement

• ASA IV

Related Conditions & MeSH terms

• Pain
• Postoperative

Intervention

Drug:
• ropivacaine

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Angers

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	decrease of postoperative pain
Secondary	decrease in morphine consumption
Secondary	duraration of analgesic effect